ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Hepatic CBP/p300 Orchestrate Amino Acid-Driven Gluconeogenesis through Histone Crotonylation.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Amino Acid Metabolism in Health and Disease.MedComm · 2026Review
- Integrated analyses of metagenomics, metabolomics and culture-based assays reveal functional roles of gut microbiota in Felidae.NPJ biofilms and microbiomes · 2026Article
- Coming to light: the transcriptional regulatory roles of histone lysine crotonylation in health and disease.Cellular & molecular biology letters · 2026Review
- The emerging paradigms of SETD family enzymes as epigenetic regulators of the immune response in inflammatory diseases.Frontiers in immunology · 2026Review
- Hepatic CBP/p300 Orchestrate Amino Acid-Driven Gluconeogenesis through Histone Crotonylation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
The role of amino acid metabolism dysregulation in the development of type 2 diabetes remains elusive. Here, significant associations of human CREBBP/EP300 gene polymorphisms with circulating amino acid and glucose levels are reported. Through integrated transcriptomic, metabolomic, and CUT&Tag analyses, the molecular mechanisms underlying these correlations are investigated. Liver-specific Crebbp/Ep300 double knockout mice display elevated plasma amino acid levels and impaired hepatic glucose production caused by the downregulation of amino acid metabolism genes, which is closely linked to altered histone crotonylation and acetylation patterns at their promoters. However, key gluconeogenic genes Pck1 and G6pc are not downregulated in knockout mice. Interestingly, the level of 2-aminoadipic acid (2-AAA), a biomarker of diabetes, is significantly increased due to decreased glutaryl-CoA dehydrogenase (GCDH) expression in CBP/p300-deficient livers. Treatment with 2-AAA or overexpression of GCDH enhances amino acid-driven gluconeogenesis through histone crotonylation-mediated transcriptional activation of amino acid metabolism genes in primary mouse hepatocytes, whereas GCDH knockdown exhibits an opposite result. Furthermore, targeted hepatic knockdown of CBP/p300 markedly attenuates hepatic glucose production from amino acids in diabetic mice. In sum, these findings underscore the pivotal role of CBP/p300 in linking amino acid catabolism to gluconeogenesis through histone crotonylation in a cell-autonomous manner.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.